Meropenem

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Sepsis

Conditions

Sepsis

Trial Timeline

Jan 1, 2002 → Jun 1, 2006

NCT ID

NCT00318552

About Meropenem

Meropenem is a approved stage product being developed by Pfizer for Sepsis. The current trial status is completed. This product is registered under clinical trial identifier NCT00318552. Target conditions include Sepsis.

What happened to similar drugs?

8 of 18 similar drugs in Sepsis were approved

Approved (8) Terminated (1) Active (9)

✅ImipenemMerckApproved

✅Drotrecogin Alfa (activated)Eli LillyApproved

✅Drotrecogin alfa (activated)Eli LillyApproved

✅Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparinEli LillyApproved

✅drotrecogin alfa (activated)Eli LillyApproved

✅Azithromycin + Azithromycin and amoxicillin + PlaceboMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00061438	Approved	Completed	Feb 1, 2003	Dec 1, 2004	Pancreatitis, Acute Necrotizing
NCT00318994	Approved	Completed	Feb 1, 2002	May 1, 2007	Pancreatitis
NCT00318552	Approved	Completed	Jan 1, 2002	Jun 1, 2006	Sepsis

Competing Products

20 competing products in Sepsis

See all competitors

Product	Company	Stage	Hype Score
Alkaline Phosphatase + Placebo	AM-Pharma	Phase 2	25
Drotrecogin alfa (activated)	Eli Lilly	Phase 2	35
Imipenem	Merck	Approved	39
Cefiderocol	Shionogi	Phase 1	29
eritoran tetrasodium + Placebo	Eisai	Phase 3	40
E5564	Eisai	Phase 2	35
Drotrecogin Alfa (Activated) + placebo	Eli Lilly	Phase 3	40
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
Drotrecogin Alfa (activated)	Eli Lilly	Approved	43
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
sPLA2 Inhibitor	Eli Lilly	Phase 1/2	32
Drotrecogin alfa (activated)	Eli Lilly	Approved	43
Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparin	Eli Lilly	Approved	43
drotrecogin alfa (activated)	Eli Lilly	Approved	43
drotrecogin alfa (activated)	Eli Lilly	Approved	43
AZD9773 (CytoFab)	AstraZeneca	Phase 2	35
AZD9773 + Placebo	AstraZeneca	Phase 2	35
AZD9773 + Placebo	AstraZeneca	Phase 2	35
AZD4144 + Placebo	AstraZeneca	Phase 2	42